Aerie Pharma (AERI) Misses Q2 EPS by 25c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
August 6, 2020 4:01 PM EDTYear-to-Date Net Revenues of $38.4 Million Increased 44% over 2019
Positive Phase 2 Topline Results for AR-1105 Implant Indicate up to Six-Month Sustained Release
AR-15512 Trial for Dry Eye, COMET-1, Set to Initiate this Year
Conference Call and Webcast Today, August 6th, at 5:00 p.m. ET
DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular... More
